AR106013A1 - Conjugados de anticuerpos modificados con cisteína - Google Patents

Conjugados de anticuerpos modificados con cisteína

Info

Publication number
AR106013A1
AR106013A1 ARP160101972A ARP160101972A AR106013A1 AR 106013 A1 AR106013 A1 AR 106013A1 AR P160101972 A ARP160101972 A AR P160101972A AR P160101972 A ARP160101972 A AR P160101972A AR 106013 A1 AR106013 A1 AR 106013A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
alkyl
group
alkenyl
linear
Prior art date
Application number
ARP160101972A
Other languages
English (en)
Inventor
Louis Miller Michael
Bai Chen
C Yoder Nicholas
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of AR106013A1 publication Critical patent/AR106013A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La solicitud proporciona además composiciones y métodos útiles para inhibir el crecimiento celular anómalo o tratar un trastorno proliferativo en un mamífero mediante el uso de los conjugados. Reivindicación 1: Un conjugado de anticuerpo y agente citotóxico representado por la fórmula (1) o una sal farmacéuticamente aceptable de esta, donde: Ab es un anticuerpo que tiene un residuo de cisteína en la posición 442 de la numeración EU/OU de una cadena pesada del anticuerpo, y se une de forma covalente a un resto de unión JCB’ mediante el grupo tiol S₄₄₂ del residuo de cisteína; D es un agente citotóxico unido de forma covalente a un enlazador L que se une de forma covalente a JCB’; y w es 1 ó 2. Reivindicación 78: Un compuesto representado mediante la fórmula estructural (2): D-L-JCB (2), o una sal farmacéuticamente aceptable de esta, donde: D se representa mediante la fórmula estructural (3); (4); (5); (6); (7); ó (8); o una sal farmacéuticamente aceptable de esta, donde: la línea doble ⁻ ⁻ ⁻ ⁻ entre N y C representa un enlace sencillo o un enlace doble, siempre que, cuando es un enlace doble, X está ausente e Y es -H, y cuando es un enlace sencillo, X se selecciona de -H, o un grupo protector de amina; e Y se selecciona de: -OR, -OCOR’, -SR, -NR’R’’, -SO₃M, -SO₂M o -OSO₃M, donde M es -H o un catión; R es -H, un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado opcionalmente sustituido que tiene de 1 a 10 átomos de carbono o un grupo PEG-(CH₂CH₂O)ₙ-Rᶜ, donde n es un entero de 1 a 24, y Rᶜ es un alquilo lineal o ramificado que tiene de 1 a 4 átomos de carbono; cada uno de R’ y R’’ se selecciona independientemente de -H, -OH, -OR, -NRRᵍ’, -COR, un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado opcionalmente sustituido que tiene de 1 a 10 átomos de carbono, un arilo opcionalmente sustituido que tiene de 6 a 18 átomos de carbono, un anillo heterocíclico 3 a 18 miembros opcionalmente sustituido que tiene de 1 a 6 heteroátomos que se selecciona de O, S, N y P, un grupo PEG-(CH₂CH₂O)ₙ-Rᶜ y Rᵍ’ es -H, un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado opcionalmente sustituido que tiene de 1 a 10 átomos de carbono o un grupo PEG-(CH₂CH₂O)ₙ-Rᶜ; X’ se selecciona del grupo que consiste en -H, -OH, un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado sustituido o no sustituido que tiene de 1 a 10 átomos de carbono, fenilo y un grupo protector de amina; Y’ se selecciona del grupo que consiste en -H, un grupo oxo, un alquinilo, alquenilo o alquilo cíclico lineal o ramificado sustituido o no sustituido que tiene de 1 a 10 átomos de carbono; A y A’ se seleccionan de -O- y -S-; W’ está ausente, o se selecciona de -O-, -N(Rᵉ)-, -N(Rᵉ)-C(=O)-, -N(C(=O)Rᵉ)-, -S- o -CH₂-S-, -CH₂NRᵉ-; Rˣ está ausente o se selecciona de un alquilo cíclico, lineal o ramificado que tiene de 1 a 10 átomos de carbono; Rᵉ es -H, un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado que tiene de 1 a 10 átomos de carbono o -(CH₂-CH₂O)ₙ-Rᵏ, donde Rᵏ es un -H, un alquilo cíclico, lineal o ramificado que tiene de 1 a 6 átomos de carbono, que porta opcionalmente un grupo amino secundario (por ejemplo, -NHR¹⁰¹) o amino terciario (-NR¹⁰¹R¹⁰²) o un heterociclo que contiene nitrógeno de 5 ó 6 miembros, donde cada uno de R¹⁰¹ y R¹⁰² es independientemente un alquinilo, alquenilo o alquilo cíclico, lineal o ramificado que tiene de 1 a 10 átomos de carbono; G; se selecciona de -CH- o -N-; R⁶ es -H, -R, -OR, -SR, -NR’R’’, -NO₂ o halógeno; -L- se representa mediante la fórmula estructural (9), donde: s3 es el sitio unido de forma covalente a JCB, y s4 es el sitio unido de forma covalente a D; E es -(CR¹⁰R¹¹)q-, cicloalquilo o cicloalquilalquilo; Z está ausente, -SO₂NR⁹-, -NR⁹SO₂-, -C(=O)-NR⁹-, -NR⁹-C(=O)-, -C(=O)-O-, -O-C(=O)-, C(=O)-NR⁹-(CH₂CH₂O)ₚ-, -NR⁹-C(=O)-(CH₂CH₂O)ₚ-, -(OCH₂CH₂)ₚ-C(=O)NR⁹-, o -(OCH₂CH₂)ₚ-NR⁹-C(=O)-; p es un entero de 1 a 1000; Q es H, un sustituyente cargado o un grupo ionizable; para cada aparición, R⁹, R¹⁰, R¹¹, R¹² y R¹³ son independientemente H o un alquilo opcionalmente sustituido; para cada aparición, q y r son independientemente un entero entre 0 y 10; y JCB es un compuesto de fórmula (10), X’-CRᵇRᶜ-C(=O)-, X’-CRᵇRᶜ-C(=O)-NRᵉ-, o un compuesto seleccionado del grupo de fórmulas (11). Reivindicación 143: El método de la reivindicación 142, donde el trastorno proliferativo es el cáncer.
ARP160101972A 2015-06-29 2016-06-29 Conjugados de anticuerpos modificados con cisteína AR106013A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186254P 2015-06-29 2015-06-29
US201662338245P 2016-05-18 2016-05-18
US15/195,269 US10898579B2 (en) 2015-06-29 2016-06-28 Conjugates of cysteine engineered antibodies

Publications (1)

Publication Number Publication Date
AR106013A1 true AR106013A1 (es) 2017-12-06

Family

ID=56409216

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101972A AR106013A1 (es) 2015-06-29 2016-06-29 Conjugados de anticuerpos modificados con cisteína

Country Status (24)

Country Link
US (2) US10898579B2 (es)
EP (2) EP3313845B1 (es)
JP (4) JP6843080B2 (es)
KR (1) KR20180021176A (es)
CN (2) CN107708810B (es)
AR (1) AR106013A1 (es)
AU (2) AU2016285929B2 (es)
CA (1) CA2988806A1 (es)
CY (1) CY1123606T1 (es)
DK (1) DK3313845T3 (es)
ES (1) ES2832527T3 (es)
HK (1) HK1254782A1 (es)
HR (1) HRP20201790T1 (es)
HU (1) HUE052616T2 (es)
LT (1) LT3313845T (es)
MA (1) MA42250B1 (es)
MD (1) MD3313845T2 (es)
PL (1) PL3313845T3 (es)
PT (1) PT3313845T (es)
RS (1) RS61050B1 (es)
RU (1) RU2733740C2 (es)
SI (1) SI3313845T1 (es)
TW (2) TWI740833B (es)
WO (1) WO2017004025A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3313884T2 (ro) 2015-06-29 2021-04-30 Immunogen Inc Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
EP3544983A2 (en) * 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
CN110267685B (zh) 2016-12-23 2023-06-20 伊缪诺金公司 靶向adam9的免疫缀合物及其使用方法
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
AU2018338205A1 (en) 2017-09-22 2020-05-07 Immunogen, Inc. Separation of triple-light chain antibodies using cation exchange chromatography
KR20200061376A (ko) 2017-09-29 2020-06-02 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 콘쥬게이트
TW202029980A (zh) 2018-10-26 2020-08-16 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020092533A2 (en) 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
SG11202104423XA (en) * 2018-11-12 2021-05-28 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
JP7437395B2 (ja) * 2018-11-12 2024-02-22 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体の調製方法
JP7401456B2 (ja) 2018-11-14 2023-12-19 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
US11833214B2 (en) * 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
CA3134403A1 (en) 2019-03-25 2020-10-01 Daiichi Sankyo Company, Limited Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DERIVATIVE CONJUGATE OF PYRROLOBENZODIAZEPINE AND A PARP INHIBITOR
JP2022533009A (ja) 2019-04-29 2022-07-21 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
CA3191395A1 (en) 2020-09-02 2022-03-10 Daiichi Sankyo Company, Limited Novel endo-.beta.-n-acetylglucosaminidase
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
KR20240113514A (ko) 2021-11-30 2024-07-22 다이이찌 산쿄 가부시키가이샤 프로테아제 분해성 마스크 항체
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
TW202346322A (zh) 2022-03-02 2023-12-01 日商第一三共股份有限公司 含Ｆｃ分子之製造方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1534674A4 (en) 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
AU2003259163B2 (en) 2002-08-16 2008-07-03 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
CA2504818C (en) 2002-11-07 2013-04-23 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
RU2545080C2 (ru) * 2009-02-05 2015-03-27 Иммьюноджен, Инк. Новые производные бензодиазепина
US8431416B2 (en) * 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011092838A1 (ja) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム コンテンツ共有システム、およびコンテンツ共有方法
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
RU2610662C9 (ru) 2010-03-12 2017-07-24 Иммьюноджен, Инк. Cd37-связывающие молекулы и их иммуноконъюгаты
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
PL2675479T3 (pl) * 2011-02-15 2016-09-30 Cytotoksyczne pochodne benzodiazepiny
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
RS58440B1 (sr) * 2014-04-11 2019-04-30 Medimmune Llc Konjugovana jedinjenja koja sadrže cistein-projektovana antitela
JP2017525755A (ja) * 2014-06-20 2017-09-07 アブジェノミクス インターナショナル インコーポレイテッド．Ａｂｇｅｎｏｍｉｃｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． Ｈｅｒ２抗体−薬物抱合体
MX2016016490A (es) 2014-06-20 2017-07-28 Bioalliance Cv Conjugados de farmaco-anticuerpo anti-receptor de folato alfa (fra) y metodos de uso de los mismos.
SG11201610624WA (en) * 2014-06-20 2017-01-27 Bioalliance Cv Anti-cd22 antibody-drug conjugates and methods of using thereof
MA42561A (fr) * 2014-09-02 2018-04-25 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicament
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
MD3313884T2 (ro) 2015-06-29 2021-04-30 Immunogen Inc Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora

Also Published As

Publication number Publication date
EP3313845A1 (en) 2018-05-02
PL3313845T3 (pl) 2021-01-11
MA42250B1 (fr) 2020-11-30
MA42250A (fr) 2018-05-02
CN107708810B (zh) 2021-10-22
RS61050B1 (sr) 2020-12-31
CN107708810A (zh) 2018-02-16
ES2832527T3 (es) 2021-06-10
JP2021088581A (ja) 2021-06-10
CN113769108A (zh) 2021-12-10
KR20180021176A (ko) 2018-02-28
US20170014522A1 (en) 2017-01-19
JP2018528162A (ja) 2018-09-27
DK3313845T3 (da) 2020-11-16
RU2017144859A3 (es) 2019-12-02
TWI740833B (zh) 2021-10-01
TW202146057A (zh) 2021-12-16
AU2016285929B2 (en) 2022-01-06
AU2022202208A1 (en) 2022-04-21
LT3313845T (lt) 2020-12-10
EP3769787A1 (en) 2021-01-27
JP2022163185A (ja) 2022-10-25
HRP20201790T1 (hr) 2021-02-05
WO2017004025A1 (en) 2017-01-05
CY1123606T1 (el) 2022-03-24
JP7441281B2 (ja) 2024-02-29
TW201705983A (zh) 2017-02-16
US20210085800A1 (en) 2021-03-25
RU2017144859A (ru) 2019-07-30
CA2988806A1 (en) 2017-01-05
HUE052616T2 (hu) 2021-05-28
PT3313845T (pt) 2020-11-19
JP6843080B2 (ja) 2021-03-17
MD3313845T2 (ro) 2021-02-28
RU2733740C2 (ru) 2020-10-06
US10898579B2 (en) 2021-01-26
JP2024067036A (ja) 2024-05-16
AU2022202208B2 (en) 2024-08-08
AU2016285929A1 (en) 2018-01-04
HK1254782A1 (zh) 2019-07-26
EP3313845B1 (en) 2020-08-12
SI3313845T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
AR106013A1 (es) Conjugados de anticuerpos modificados con cisteína
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CO2017011172A2 (es) Compuestos de 1-ciano-pirrolidina como inhibidores de usp30
AR102094A1 (es) Inhibidores de proteínas kras con una mutación g12c
AR120700A1 (es) Inhibidores de kras g12c
NZ711064A (en) Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
CY1121077T1 (el) Αναστολεις της κυκλινο-εξαρτωμενης κινασης 7 (cdk7)
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PE20181067A1 (es) Conjugados de anticuerpo-farmaco de pirrolobenzodiazepina y metodos de uso
BR112019006816A8 (pt) Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR051388A1 (es) Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
PE20141209A1 (es) Inhibidores de la replicacion de virus influenza
CR20160099A (es) Formulación de inhibidores de la syk
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
UY32490A (es) Inhibidores de beta-secretasa
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
PE20170775A1 (es) Derivados de benzodiazepina citotoxicos
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
MX2021004380A (es) Derivados de flavaglina para inhibicion de activacion del oncogen kras.
CU20190029A7 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos